Faron Pharmaceuticals Share Price | |
---|---|
Price | 93.50 |
Bid | 92.00 |
Ask | 95.00 |
Change | 0.00 (0.00%) |
Volume | 0 |
Open | 0.00 |
High | 0.00 |
Low | 0.00 |
Prev. Close | 93.50 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 104.62m |
Market Capitalisation | £97.82m |
Market Size | 750 |
52 Week High | 360.00 |
52 Week High Date | 11-Dec-2023 |
52 Week Low | 89.00 |
52 Week Low Date | 20-Jun-2024 |
# Trades | 0 |
---|---|
Vol. Sold | 0 |
Sold Value | £N/A |
Vol. Bought | 0 |
Bought Value | £N/A |
PE Ratio | -2.697491 |
Earnings | -34.66184 |
Dividend | 0.00 |
Yield | 0.00% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
02-Jul-24 | 14:42:08 | 93.65 | 114 | Buy* | 92.00 | 95.00 | 106.76 | O Ordinary |
02-Jul-24 | 14:33:15 | 95.00 | 229 | Buy* | 92.00 | 95.00 | 217.55 | O Ordinary |
02-Jul-24 | 13:47:45 | 93.08 | 5,000 | Sell* | 92.00 | 95.00 | 4,654 | O Ordinary |
02-Jul-24 | 11:55:28 | 95.00 | 45 | Buy* | 92.00 | 95.00 | 42.75 | O Ordinary Trade was executed as an SI |
02-Jul-24 | 11:36:14 | 95.00 | 5,000 | Buy* | 90.00 | 95.00 | 4,750 | O Ordinary |
02-Jul-24 | 11:35:09 | 95.00 | 5,000 | Buy* | 90.00 | 95.00 | 4,750 | O Ordinary |
02-Jul-24 | 11:34:36 | 95.00 | 4,988 | Buy* | 90.00 | 95.00 | 4,739 | O Ordinary |
02-Jul-24 | 11:33:03 | 94.80 | 4,207 | Buy* | 90.00 | 95.00 | 3,988 | O Ordinary |
02-Jul-24 | 11:31:50 | 95.00 | 5,251 | Buy* | 90.00 | 95.00 | 4,988 | O Ordinary |
02-Jul-24 | 11:30:59 | 93.99 | 6,371 | Buy* | 90.00 | 95.00 | 5,988 | O Ordinary |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
04-Apr-24 | 03-Apr-24 | Placing | Tuomo Pätsi held the position of Non-Executive Director at the time of this trade.Tuomo Pätsi | 1.50 | EUR | 13,333 | 250,980 |
04-Apr-24 | 03-Apr-24 | Placing | Markku Jalkanen held the position of CEO at the time of this trade.Markku Jalkanen | 1.50 | EUR | 33,333 | 2,208,599 |
27-Oct-23 | 12-Oct-23 | Sell | John Poulos held the position of Independent Non-Executive Director at the time of this trade.John Poulos | 382.59 | GBX | 5,000 | 10,000 |
27-Oct-23 | 03-Oct-23 | Sell | John Poulos held the position of Independent Non-Executive Director at the time of this trade.John Poulos | 372.09 | GBX | 5,000 | 10,000 |
31-Aug-23 | 28-Aug-23 | Exercise of Option | John Poulos held the position of Independent Non-Executive Director at the time of this trade.John Poulos | 1.09 | EUR | 20,000 | 20,000 |
We offer a promising immunotherapy candidate with a new target to fight cancer.